NasdaqGS:AMGNBiotechs
Amgen’s Repatha Diabetes Data Reframes Cardiometabolic Upside For Investors
Amgen (NasdaqGS:AMGN) presented new VESALIUS-CV Phase 3 data for Repatha in high-risk diabetes at the ADA 86th Scientific Sessions in 2026.
The trial reported a significant reduction in major cardiovascular events for high-risk diabetic patients treated with Repatha.
Results were also published in major medical journals, underscoring clinical relevance for cardiometabolic care.
The findings highlight a large, underserved patient group within diabetes and obesity management where current...